Novel TSPO Ligand 2-Cl-MGV-1 Can Counteract Lipopolysaccharide Induced Inflammatory Response in Murine RAW264.7 Macrophage Cell Line and Lung Models
Cells · 2024
DOI: 10.3390/cells13201702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Fadi Obeid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel. Hauptthemen laut MEDLINE: Lipopolysaccharides, Mice, Inbred C57BL, Macrophages. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We assessed the anti-inflammatory activity of the TSPO ligand 2-Cl-MGV-1. Lipopolysaccharide (LPS) was used to induce inflammatory response in a murine RAW264.7 macrophage model (LPS: 100 ng/mL) and a mouse model (C57BL/6) of lung inflammation (LPS: 5 mg/kg). In the macrophage model, the presence of 2-Cl-MGV-1 (25 µM) caused the LPS-induced elevation in nitrite levels to decrease by 70% (p < 0.0001) and interleukin (IL)-6 by 50% (p < 0.05). In the mouse model, 2-Cl-MGV-1, administered 30 min before, or co-administered with, an LPS injection, significantly inhibited the elevation in serum IL-5 levels (both by 65%; p < 0.001 and p < 0.01, respectively). 2-Cl-MGV-1 administration to mice 30 min before LPS injection and 1 h thereafter significantly inhibited the elevation in IL-1β serum levels (both by 63%, p < 0.005). IL-6 elevation was inhibited by 73% (p < 0.005) when 2-Cl-MGV-1 was administered 30 min before LPS, by 60% (p < 0.05) when co-administered with LPS, and by 64% (p < 0.05) when administered 1 h after LPS. All cytokine assessments were conducted 6 h post LPS injection. Histological analyses showed decreased leukocyte adherence in the lung tissue of the ligand-treated mice. 2-Cl-MGV-1 administration 30 min prior to exposure to LPS inhibited inflammation-induced open field immobility. The beneficial effect of 2-Cl-MGV-1 suggests its potential as a therapeutic option for inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel.
- Institute of Pathology and Cytology, Rambam Health Care Campus, P.O. Box 9602, Haifa 3109601, Israel.
- Laboratory of Biological and Molecular Psychiatry, Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
- Research Unit, Geha Mental Health Center, Petah Tikva 4910002, Israel.
ORCID-Profile: Sheelu Monga, Abraham Weizman
Zitieren
APA
Obeid, F., Kahana, M., Dahle, B., Monga, S., Zohar, Y., Weizman, A., & Gavish, M. (2024). Novel TSPO Ligand 2-Cl-MGV-1 Can Counteract Lipopolysaccharide Induced Inflammatory Response in Murine RAW264.7 Macrophage Cell Line and Lung Models. Cells. https://doi.org/10.3390/cells13201702
Vancouver
Obeid F, Kahana M, Dahle B, Monga S, Zohar Y, Weizman A, et al. Novel TSPO Ligand 2-Cl-MGV-1 Can Counteract Lipopolysaccharide Induced Inflammatory Response in Murine RAW264.7 Macrophage Cell Line and Lung Models. Cells. 2024. doi:10.3390/cells13201702
BibTeX
@article{Obeid2024,
author = {Obeid, Fadi and Kahana, Meygal and Dahle, Baraah and Monga, Sheelu and Zohar, Yaniv and Weizman, Abraham and Gavish, Moshe},
title = {Novel TSPO Ligand 2-Cl-MGV-1 Can Counteract Lipopolysaccharide Induced Inflammatory Response in Murine RAW264.7 Macrophage Cell Line and Lung Models},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13201702}
}
EUVIMED